Ondansetron Treatment in Tourette's Disorder: A 3-Week, Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The aim of the present study was to evaluate the efficacy of ondansetron, a selective 5-HT(3) antagonist, in the treatment of Tourette's disorder. METHOD: Participants (N = 30) aged 12 to 46 years, diagnosed with DSM-IV Tourette's disorder and resistant to previous haloperidol treatment, were enrolled in a 3-week, randomized, double-blind, placebo-controlled outpatient study. Assessments were conducted at baseline and once a week during the study period. Scales used included the Tourette's Syndrome Global Scale (TSGS), the Yale Global Tic Severity Scale (YGTSS), and the Yale-Brown Obsessive Compulsive Scale. Ondansetron dose was 8, 16, and 24 mg/day in the first, second, and third weeks, respectively. RESULTS: A significant positive effect of ondansetron on tic severity, as assessed by the TSGS, was noted (baseline vs. endpoint: mean +/-SD = 29.62 +/-20.33 vs. 20.58 +/-12.82, p = .002 vs. placebo). However, no significant effect was detected upon assessing ondansetron/ placebo effect on tic severity with the YGTSS (baseline vs. endpoint: mean +/-SD = 24.04 +/-9.44 vs. 17.50 +/-9.48, p = .15 vs. placebo). No change in obsessive-compulsive symptoms was noted in either group. Adverse effects included mild and transient abdominal pain. CONCLUSIONS: Ondansetron may have antitic effects in patients with Tourette's disorder. Large-scale, double-blind studies should further assess the antitic efficacy of ondansetron.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, several smaller pilot trials showed that repeated dosing of ondansetron over multiple weeks reduced overall symptom severity in OCD [106–107] and TS [108], with potential utility as an augmentation strategy in SSRI-resistant OCD [106].”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [108]
In the citing paper
“54% of patients in the ondansetron group and 21% in the placebo group were considered improved”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [112]
Citations
Cites
Still being checked.
Cited by
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders
Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.09.015 · Cited by 276
Pringsheim, T., Holler-Managan, Y., Okun, M. S., Jankovic, J., Piacentini, J., Cavanna, A. E., Martino, D., Müller-Vahl, K., Woods, D. W., Robinson, M., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007467 · Cited by 252
Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder
Shephard, E., Stern, E. R., van den Heuvel, O. A., Costa, D. L. C., Batistuzzo, M. C., Godoy, P. B. G., Lopes, A. C., Brunoni, A. R., Hoexter, M. Q., Shavitt, R. G., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-01007-8 · Cited by 250
Tourette Syndrome and Tic Disorders: A Decade of Progress
SWAIN, J. E., SCAHILL, L., LOMBROSO, P. J., KING, R. A., & LECKMAN, J. F. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318068fbcc · Cited by 238
Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy
Pringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Luscombe, S., Steeves, T., et al. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700302 · Cited by 191
Hollis, C., Pennant, M., Cuenca, J., Glazebrook, C., Kendall, T., Whittington, C., Stockton, S., Larsson, L., Bunton, P., Dobson, S., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20040 · Cited by 119
Ramamoorthy, R., Radhakrishnan, M., & Borah, M. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f3cfd4 · Cited by 130
Treatment of tics and Tourette syndrome
Singer, H. S. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0095-4 · Cited by 97
Current controversies on the role of behavior therapy in Tourette syndrome
Scahill, L., Woods, D. W., Himle, M. B., Peterson, A. L., Wilhelm, S., Piacentini, J. C., McNaught, K., Walkup, J. T., & Mink, J. W. (2013) · Movement Disorders · doi:10.1002/mds.25488 · Cited by 84
Singer, H. S. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000752 · Cited by 138
Whittington, C. J., Pennant, M. E., Kendall, T., Glazebrook, C., Trayner, P., Groom, M. J., Hedderly, T. J., Heyman, I., Jackson, G. M., Jackson, S. R., et al. (2016) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12556 · Cited by 183
Tic Disorders: Neural Circuits, Neurochemistry, and Neuroimmunology
Harris, K., & Singer, H. S. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210080901 · Cited by 117
Shprecher, D., & Kurlan, R. (2009) · Movement Disorders · doi:10.1002/mds.22378 · Cited by 126
Treatment of Children and Adolescents With Tics and Tourette Syndrome
Gilbert, D. L. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210080401 · Cited by 112
Clinical characteristics of children and adolescents with a primary tic disorder
Specht, M. W., Woods, D. W., Piacentini, J., Scahill, L., Wilhelm, S., Peterson, A. L., Chang, S., Kepley, H., Deckersbach, T., Flessner, C., et al. (2011) · Journal of Developmental and Physical Disabilities · doi:10.1007/s10882-010-9223-z · Cited by 74
Review: The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?
Rajkumar, R., & Mahesh, R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109348161 · Cited by 116
Farhat, L. C., Behling, E., Landeros‐Weisenberger, A., Levine, J. L. S., de Barros, P. M. F., Wang, Z., & Bloch, M. H. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00316-9 · Cited by 88
Tic disorders: from pathophysiology to treatment
Rampello, L., Alvano, A., Battaglia, G., Bruno, V., Raffaele, R., & Nicoletti, F. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0008-8 · Cited by 75
Tourette disorder and other tic disorders
Deeb, W., Malaty, I. A., & Mathews, C. A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00008-3 · Cited by 73
Tourette syndrome and other chronic tic disorders: an update on clinical management
Martino, D., & Pringsheim, T. M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1413938 · Cited by 66
Dooley, J. M. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.09.004 · Cited by 61
Trials of pharmacological interventions for Tourette syndrome: a systematic review.
Waldon, K., Hill, J., Termine, C., Balottin, U., & Cavanna, A. E. (2013) · Europe PMC (PubMed Central) · doi:10.3233/ben-2012-120269 · Cited by 53
Treatment of tics associated with Tourette syndrome
Jankovic, J. J. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-019-02105-w · Cited by 54
Scales for hyperkinetic disorders: A systematic review
Pietracupa, S., Bruno, E., Cavanna, A. E., Falla, M., Zappia, M., & Colosimo, C. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.08.1544 · Cited by 49
Pharmacotherapeutics of Tourette Syndrome and Stereotypies in Autism
Rajapakse, T., & Pringsheim, T. M. (2010) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2010.10.008 · Cited by 37
Pharmacotherapy of Adolescent Substance Use Disorders: AReview of the Literature
Waxmonsky, J. G., & Wilens, T. E. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.810 · Cited by 38
Nondopaminergic neurotransmission in the pathophysiology of Tourette syndrome.
Udvardi, P. T., Nespoli, E., Rizzo, F., Hengerer, B., & Ludolph, A. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00004-4 · Cited by 33
Are 5‐HT3antagonists effective in obsessive–compulsive disorder? A systematic review of literature
Serata, D., Kotzalidis, G. D., Rapinesi, C., Janiri, D., Di Pietro, S., Callovini, G., Piacentino, D., Gasperoni, C., Brugnoli, R., Ferri, V. R., et al. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2461 · Cited by 30
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions
Stern, E. R., Shahab, R., Grimaldi, S. J., Leibu, E., Murrough, J. W., Fleysher, L., Parides, M. K., Coffey, B. J., Burdick, K. E., & Goodman, W. K. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0174-x · Cited by 27
“Although prior studies have found that ondansetron was an effective treatment for several conditions, including pruritus [23], neuropathic pain [24], OCD [25–27], TD [28], alcohol-dependence [29], schizophrenia [30], and bulimia [31], other research has been more conflicting with regard to ondansetron’s effectiveness,…”
BackgroundResultLennertz, L., Wagner, M., Grabe, H. J., Franke, P. E., Guttenthaler, V., Rampacher, F., Schulze‐Rauschenbach, S., Vogeley, A., Benninghoff, J., Ruhrmann, S., et al. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.003 · Cited by 30
Tic Suppression: The Medical Model
Wu, S. W., Harris, E., & Gilbert, D. L. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0015 · Cited by 16
Management of tics and Tourette's disorder: an update
Bestha, D. P., Jeevarakshagan, S., & Madaan, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.486402 · Cited by 15
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14f09704 · Cited by 14
Stern, E. R., Collins, K. A., Bragdon, L. B., Eng, G. K., Recchia, N., Coffey, B. J., Leibu, E., Murrough, J. W., Tobe, R. H., Iosifescu, D. V., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240294 · Cited by 13
Andrade, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14f09292 · Cited by 9
Kang, S., Lee, H., Yoon, H., Cho, S. N., Park, Y. M., & Kim, L. (2012) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2012.732114 · Cited by 9
de Barros, P. M. F., Farhat, L. C., Behling, E., Nasir, M., Landeros‐Weisenberger, A., & Bloch, M. H. (2024) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2024.10.011 · Cited by 10
Pharmacotherapies to tics: a systematic review
Zhang, Z., Yang, C., Zhang, L., Yi, Q., Liu, B., Zeng, J., & Yu, D. (2018) · Oncotarget · doi:10.18632/oncotarget.25080 · Cited by 5
Martino, D., Espay, A. J., Fasano, A. A., & Morgante, F. (2015) · Springer eBooks · doi:10.1007/978-3-662-48468-5_3 · Cited by 7
The Successful Use of Ondansetron in a Boy With Both Leukemia and Tourette Syndrome
Rizzo, R., Marino, S., Gulisano, M., & Robertson, M. M. (2007) · Journal of Child Neurology · doi:10.1177/0883073807307085 · Cited by 4
Pharmacological treatment of Tourette’s syndrome: from the past to the future
Gong, H., Du, X., Su, A., & Du, Y.-W. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07172-2 · Cited by 5
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00016-0 · Cited by 4
Prise en charge thérapeutique des tics dans la maladie de Gilles de Tourette
Diallo, R., Welter, M., & Mallet, L. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)90412-9 · Cited by 4
Neurotransmitter abnormalities in primary tic disorders and Tourette syndrome
Worbe, Y., & Pasquereau, B. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-13554-5.00023-7 · Cited by 3
Ghosh, D., & Ghosh, D. (2024) · Journal of Modern Medicine · doi:10.4103/jomm.jomm_10_24 · Cited by 3
THE USE OF LEVETIRACETAM TO TREAT TICS IN CHILDREN AND ADOLESCENTS WITH TOURETTE SYNDROME
Awaad, Y. M. (2006) · Neuropediatrics · doi:10.1055/s-2006-945583 · Cited by 3
Monfrini, E., Saleh, C., Servello, D., Jaszczuk, P., & Porta, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188831 · Cited by 3
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00015-9 · Cited by 2
Clinical Rating Instruments in Tourette Syndrome
Cavanna, A. E. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197543214.003.0021 · Cited by 1
The use of ondansetron in psychiatry: An educational article and expert opinion
Al-Mosawi, A. J. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i8.5927 · Cited by 5
Sachdev, R. A., Ruparelia, R., Reid, J. E., Mpavenda, D., Cinosi, E., & Fineberg, N. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.016 · Cited by 2
The pharmacological treatment of Tourette syndrome
Baizabal‐Carvallo, J. F., & Jankovic, J. J. (2022) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.12.007 · Cited by 1
Tourette Syndrome and the Spectrum of Neurodevelopmental Tic Disorders
Bernard, G., Lespérance, P., Richer, F., & Chouinard, S. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-120-2_4
Pharmacological Management of Tic Disorders in Youth
Saggu, B. M., Shad, S., Barnes, A. A., & Budman, C. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811980-8.00004-2 · Cited by 2
TRATAMIENTO FARMACOLÓGICO DEL TDAH Y LAS COMORBILIDADES
Prince, J. B., & Wilens, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-84-458-2021-6.00019-1
Lennington, J. B., Bloch, M. H., Scahill, L. D., Szuhay, G., Lombroso, P. J., & Vaccarino, F. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00107-8
Gilles de la Tourette syndrome: the complexities of phenotype and treatment – further information
(2011) · British Journal of Hospital Medicine · doi:10.12968/hmed.2011.72.2.s1
Gilles de la Tourette Syndrome
Ghosh, D., & Ghosh, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00145-7
Metadata
- Authors
- Toren, P., Weizman, A., Ratner, S., Cohen, D., & Laor, N.
- ORCID
- Weizman, Abraham
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-04-15
- Volume
- 66
- Issue
- 04
- Pages
- 499-503
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2003790674
- Cited by
- 60
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 2 · 2013: 5 · 2012: 3
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Stuttering Research and Treatment
- Keywords
- ondansetron, Tourette syndrome, tic severity, 5-HT3 receptor antagonists, obsessive-compulsive symptoms, antitoxic effect, adverse effects
- MeSH terms
- Adolescent, Adult, Child, Double-Blind Method, Female, Tourette Syndrome, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Serotonin Antagonists, Severity of Illness Index, Treatment Outcome, Ondansetron
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.